MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation ; volume:15 ; number:1 ; day:6 ; month:2 ; year:2015 ; pages:1-8 ; date:12.2015
BMC cancer ; 15, Heft 1 (6.2.2015), 1-8, 12.2015
- Creator
-
Noro, Rintaro
Seike, Masahiro
Zou, Fenfei
Soeno, Chie
Matsuda, Kuniko
Sugano, Teppei
Nishijima, Nobuhiko
Matsumoto, Masaru
Kitamura, Kazuhiro
Kosaihira, Seiji
Minegishi, Yuji
Yoshimura, Akinobu
Kubota, Kaoru
Gemma, Akihiko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1019-1
- URN
-
urn:nbn:de:101:1-2021081719412334707229
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Noro, Rintaro
- Seike, Masahiro
- Zou, Fenfei
- Soeno, Chie
- Matsuda, Kuniko
- Sugano, Teppei
- Nishijima, Nobuhiko
- Matsumoto, Masaru
- Kitamura, Kazuhiro
- Kosaihira, Seiji
- Minegishi, Yuji
- Yoshimura, Akinobu
- Kubota, Kaoru
- Gemma, Akihiko
- SpringerLink (Online service)
Other Objects (12)
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model
Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model
Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model